MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Core Insights - MetaVia Inc. has initiated the first patient dosing in the 8-week 48 mg MAD cohort of its Phase 1 clinical trial for DA-1726, targeting obesity, with top-line data expected by the end of 2025 [1][2] - The company reported $14.3 million in cash at the end of Q3 2025, which is anticipated to fund operations into 2026 [1][12] Company Developments - The Phase 1 data for DA-1726 presented at ObesityWeek® 2025 indicated a strong safety and tolerability profile, with participants experiencing up to a 6.3% mean body-weight reduction and waist circumference decreases of up to 3.9 inches [2][5] - The pharmacokinetic data for DA-1726 showed a linear, dose-proportional exposure and an approximately 80-hour half-life, supporting the feasibility of once-weekly dosing [2] - MetaVia is preparing for an end-of-Phase 2 meeting with the FDA in the first half of 2026 regarding vanoglipel (DA-1241), which has shown meaningful reductions in liver fat and inflammation in Phase 2a trials [2][7] Financial Performance - Research and Development (R&D) expenses for Q3 2025 were approximately $1.9 million, down from $4.5 million in Q3 2024, primarily due to lower direct R&D expenses related to both DA-1241 and DA-1726 [6][7] - General and Administrative (G&A) expenses for Q3 2025 were approximately $1.6 million, slightly down from $1.7 million in Q3 2024 [6][7] - The net loss for Q3 2025 was $3.4 million, or $0.14 per share, compared to a net loss of $5.7 million, or $0.55 per share, in Q3 2024 [12][14]